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Proper cell fate decisions require precise and coordinated changes in gene 
expression. Alterations in gene expression proceed through the functions of 
transcription factors, their associated coregulators and histone modifying 
enzymes. However, how these complex and diverse groups of proteins and 
enzymes coordinate their respective functions at target genes remains largely 
unknown. To gain additional insights into the coordinated activities of transcription 
factors and histone modifying enzymes, we studied how the transcription factor 
growth factor independence 1 (GFI1) carries out transcriptional repression through 
interaction with coregulator histone modifying enzymes. GFI1 is a transcriptional 
repressor and master regulator of normal and malignant hematopoiesis. GFI1 is 
comprised of a transcriptionally repressive N-terminal Snail/Slug/GFI1 (SNAG) 
domain, a C-terminal concatemer of DNA binding zinc fingers and a linker region 
which separates them. The relatively simple protein domain structure of GFI1 
makes it an ideal transcription factor for studying mechanisms of transcriptional 
repression. We describe here two novel mechanisms of transcriptional repression 
by GFI1, both of which occur through posttranslational modification. First, we 
identify and characterize a SUMOylation event carried out by the SUMO2/3, UBC9, 
and PIAS3 SUMOylation machinery. SUMOylation occurs at K239 within a type I 
SUMO consensus element in the linker region of GFI1. We find that SUMO 
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defective GFI1 derivatives fail to complement Gfi1 depletion phenotypes in 
zebrafish developmental erythropoiesis and in granulocyte differentiation in 
cultured human cells. SUMO defective GFI1 derivatives also display impaired 
LSD1/CoREST binding and fail to repress the GFI1 target gene MYC during 
granulocyte differentiation and enforced MYC expression blocks GFI1 mediated 
granulocyte differentiation. Second, we show SMYD2 mediated methylation at K8 
within the GFI1 SNAG domain is a critical determinant of GFI1 transcriptional 
repression and contributes to GFI1 hematopoietic differentiation and leukemia cell 
survival functions. The methylation defective GFI1 SNAG domain lacks repressor 
function due to a failure of LSD1 recruitment and accumulation of promoter H3K4 
dimethyl marks. Our findings here suggest GFI1 SUMOylation and methylation are 
part of a series of regulatory inputs that regulate GFI1 function. From these data 
we propose SNAG domain methylation and linker region SUMOylation coordinate 
LSD1/CoREST recruitment and enable CoREST dependent activation of LSD1 
H3K4 demethylase activity for repression of GFI1 target genes. Our findings add 
GFI1 to the growing roster of transcription factors regulated by posttranslational 
modification and provides a rare mechanistic understanding into how these 
modifications regulate transcription factor functions through the recruitment 
histone modifying enzyme effectors.
 To everyone who supported my scientific curiosity. 
 “This is water, this is water.” 
David Foster Wallace
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Gene expression controls cellular identity and function 
Transcription factors modulate gene expression to dictate  
cellular functions 
 Higher organisms, including humans, rely on the coordinated functions of 
distinct cell types to maintain organism homeostasis. Over 200 cell types are 
present within the human body, each with unique and indispensable functions that 
contribute to organism homeostasis. However, each of these functionally distinct 
cell types harbors an identical genome. How this remarkable level of functional 
diversity arises from an identical genome remains a profound question of modern 
molecular genetics. It is now appreciated that identical genomes achieve functional 
diversity by precisely and accurately regulating gene expression. Such a model of 
functional diversity through genetic simplicity predicts all cells types retain the 
potential to become any functionally distinct cell type. This prediction has now been 
realized in landmark findings demonstrating cell identity is remarkably plastic and 
cell identity can be altered by the introduction of a surprisingly small number of 
genetic factors (1).  
 Genetic factors with such profound impacts on cell identity and function are 
predominantly transcription factors, proteins capable of binding and regulating the 
transcriptional status of specific deoxyribonucleic acid (DNA) sequences. Of the 
roughly 20,000 protein coding genes in the human genome, it is estimated that 
2,000 genes encode transcription factors (2). Many of these transcription factors 
have been appropriately dubbed “master regulators” and “pioneering” factors. One 
such master regulator was described roughly 30 years ago. In a series of elegant 
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papers, Weintraub and colleagues described a gene that was sufficient for 
converting fibroblasts to myoblasts (3, 4). How this gene accomplishes such a 
remarkable feat would later be clarified, but Weintraub’s group named the gene 
myoblast determination gene number 1, or MyoD1, and speculated that, 
“Eventually, this information, together with input from local cues, could focus down 
to the activation of only one or a few specific genes that are ultimately responsible 
for determining a specific cell type.” Master regulator transcription factors have 
been identified for many cell types, from myogenic cells (MyoD) back in 1986 to 
pluripotent cells (Oct4, Sox2, Klf4, Myc) in 2006 (1, 3, 4). Transcription factors are 
also often dysregulated in a variety of human diseases including cancer (5). These 
examples highlight the power of transcription factors to dictate cell identity, fate, 
and function. 
 Transcription factors exert their influence on cell fate and function through 
their ability to directly bind DNA and alter gene expression. Specific protein 
domains that confer DNA binding potential to proteins have been identified. These 
domains include, but are not limited to, C2H2 type zinc-nuclease fingers, 
homeodomains, helix loop helixes, basic leucine zippers, and nuclear hormone 
receptors (2). And while these domains are distinct in structure, they all share the 
ability to directly bind DNA in sequence specific manner, utilizing specific hydrogen 
bond donor and acceptor patterns within the major groove of consensus DNA to 
do so (2). Meta analysis of human transcription factors based on functional 
annotation reveals transcription factors contribute to a diverse range of biological 
processes, including, cellular, reproductive, developmental, metabolic, and 
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immune system processes as well as cellular localization and responses to stimuli 
(2). Furthermore, normal human tissues express roughly 150 to 300 transcription 
factors, with more functionally complex tissues such as fetal lung, brain, and 
placenta expressing more transcription factors, while more quiescent tissues such 
as appendix, skeletal muscle, and skin expressing fewer transcription factors (2). 
It is now well established that transcription factors coordinate expression of specific 
gene networks capable of altering and reinforcing cell fates and functions.  
 
Chromatin structure regulates gene expression 
Chromatin structure 
 Transcription factors were previously generalized as transcriptional 
activators or transcriptional repressors, either promoting or deterring transcription 
from nearby genes. And indeed, similar simplistic mechanisms of activator and 
repressor antagonism exist in bacteria and lower organisms. In eukaryotes, 
however, transcription factors exert their influence on gene expression through a 
variety of coregulators and histone modifying enzymes that alter chromatin 
structure. Chromatin is generally defined as the DNA of the host genome and the 
associated proteins that package the genome (6).  
Chromatin is the functional unit of DNA in the genome and chromatin 
function is a reflection of its structure. Chromatin is comprised of nucleosomes, 
each of which is comprised of roughly 147 base pairs of DNA wrapped around 
histone protein octamer (Figure 1.1). Nucleosome histone octamers consist of two 
copies of each of the four canonical histone proteins: H2A, H2B, H3, and H4  which 
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form a globular protein scaffold for DNA to wrap around (Figure 1.1) (7). DNA 
maintains nucleosome contact through numerous weak electrostatic interactions 
between positively charged histone residues and negatively charged phosphate 
groups in the DNA backbone (6). Wrapping of DNA around a nucleosome 
constitutes the primary function of chromatin, which is the compaction of DNA. It 
is this packaging by histones and higher orders of chromatin compaction that 
allows roughly two linear meters of genomic DNA to be packaged into the 
microscopic nucleus of every cell, a level of compaction that is estimated to be 
over 10,000 fold. 
From a level of increasing chromatin compaction, double stranded DNA is 
initially wrapped around individual nucleosomes with intervening DNA sequence 
not bound by nucleosomes. This wrapping constitutes a “beads on a string” 
structure, where nucleosomes are “beads” and intervening DNA is “string” (Figure 
1.1). Condensing and repositioning nucleosomes within this “beads on a string” 
structure, as well as binding of histone H1 to “string” DNA results in formation of a 
30 nanometer (nm) fiber (Figure 1.1). Additional rolling and looping of 30 nm fibers 
onto themselves results in extended and eventually condensed chromosome 
conformations (Figure 1.1). Finally, organization of these condensed looping 
chromatin formations leads to formation of the mitotic chromosomes consisting of 







To exert their biological functions, transcription factors must bind their 
specific consensus DNA sequence. However, high degrees of chromatin 
compaction deter transcription factor binding by concealing consensus DNA 
sequences on nucleosome surfaces or by burying consensus sequences deep 
within higher order chromatin structures called heterochromatin. Conversely, DNA 
sequences with less condensed euchromatin structures are considered accessible 
to transcription factors.  
The composition of histone proteins within nucleosomes alter the relative 
composition of heterochromatin and euchromatin by augmenting chromatin 
compaction. Canonical nucleosomes within the genome are comprised of two 
copies of H2A, H2B, H3, and H4 histones. However, no fewer than 55 histone 
variants have been identified in humans (8). Incorporation of noncanonical 
histones within nucleosomes can dramatically alter chromatin function. For 
example, CENPA is a centromere specific histone H3 variant incorporated into 
nucleosomes at heterochromatic centromeres during mitosis (9). CENPA 
deposition at centromeres is required for kinetochore and spindle assembly 
formation and experimentally mistargeting CENPA to noncentromeric regions 
assembles centromere kinetochore machinery at these sites (10). CENPA is also 
deposited at sites of DNA damage (11). CENPA deposition is independent of γ 
H2AX deposition, a phosphorylated histone variant also deposited at sites of DNA 
damage (12). These examples demonstrate the profound impact on chromatin 
function histone variants can have. 
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DNA methylation and demethylation 
While DNA packaging histones are critical for chromatin functions, 
modification of DNA itself can also influence chromatin function. DNA methylation 
is the covalent addition of methyl groups to the fifth carbon position of cytosine 
bases within DNA. DNA methylation predominantly occurs in a CpG dinucleotide 
context where a cytosine base is followed by a guanine base. This context allows 
for the maintenance of DNA methylation marks following DNA replication, a 
maintenance function carried out by the DNA methyltransferase enzyme DNMT1 
(13). DNMT1 specifically recognizes and methylates the unmethylated cytosine 
base within a hemimethylated CpG, a CpG where only one complementary strand 
cytosine is methylated. DNA methylation marks can also be deposited at 
unmethylated CpGs de novo by the DNA methyltransferases DNMT3A and 
DNMT3B (13). DNA methylation is transcriptionally repressive, owing to its ability 
to recruit chromatin compacting enzymes and cofactors. DNA methylation is critical 
for a variety of developmental processes, including most notably X chromosome 
inactivation (14).  
 Long considered a permanent mark, it is now understood that DNA 
methylation marks can be removed. Early reports correctly asserted that passive 
DNA demethylation may occur from a failure to maintain methylation following DNA 
replication. However, it is now understood that active DNA demethylation also 
occurs and is critical for a variety of cellular and developmental processes (15). 
While alternative mechanisms have been proposed, the preponderance of 
evidence suggests DNA demethylation occurs through the oxidation of 5-
8 
 
methylcytosine bases followed by base excision repair. Oxidation of 5-
methylcytosine (5mC) bases occurs through the activity of ten-eleven translocase 
(TET) enzymes, resulting in the formation of 5-hydroxymethylcytosine (5hmC) 
bases. 5hmC bases can also be further oxidized to generate 5-formylcytosine (5fC) 
and 5-carboxylcytosine (5caC) bases (15). 5fC and 5caC bases are recognized 
and removed by the base excision repair activity of thymine DNA glycosylase 
(TDG) enzymes, generating an abasic site. Repair of the abasic site using an 
unmethylated cytosine base then results in demethylation (15).  
 
Histone posttranslational modification and the  
histone code hypothesis 
Similar to DNA methylation, covalent modification of histone proteins 
dynamically regulates chromatin structure and function. Pioneering work by 
Vincent Allfrey in 1964 demonstrated histones are subject to acetylation and 
methylation and these modifications are associated with specific transcriptional 
states (16). Canonical and noncanonical histone proteins have been found to be 
modified by a variety of posttranslational modifications, including acetylation, 
methylation, phosphorylation, ubiquitination, SUMOylation, and ribosylation (8). 
These modifications can occur within the globular domains of histones, however; 
the functional consequences of modifications within the N-terminal tail of histone 
proteins has been more thoroughly described. Histone tails extend from the 
globular nucleosome and are largely unstructured, allowing access for enzymes 
responsible for writing, reading, and erasing posttranslational modifications. In 
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humans, an increasingly complex suite of over 150 enzymes regulate histone 
posttranslational marks (8). Furthermore, more than 100 unique histone residues 
are modified by posttranslational modification (8). Cataloguing the enzymes 
responsible for the deposition and removal of methyl and acetyl marks on a subset 
of H3 lysines, K4, K9, K27, and K36 highlights the impressive amount of 
combinatorial diversity present within the H3 tail (Figure 1.2). These lysine 
methylation and acetylation events are a small subset of the posttranslational 
modifications that occur on histone proteins. Descriptions of where these 
modifications occur in the genome, the transcriptional status of nearby genes and 
whether these modifications occur independently or coincident with other 
modifications has led to the “histone code” hypothesis. This hypothesis posits that 
the distinct combinations of histone modifications, either directly, or indirectly 
through the action of other effector proteins, dictate chromatin function, including 
the transcriptional status of associated genes.  
The logic of the histone code hypothesis has classified proteins as histone 
writers, readers, and erasers (17). Writers are enzymes capable of catalytically 
adding posttranslational modifications to histone substrates at specific residues. 
Readers are proteins capable of binding specific histone modifications, while 
erasers are enzymes capable of removing histone modifications (17).  
Of the impressive breadth of histone posttranslational modifications, lysine 
methylation is perhaps the most well characterized histone modification. Lysine 
methylation occurs on H1, H2B, H3, and H4 histones (8). Histone H3 tail 
methylation occurs at K4, K9, K20, K27, and K36 (Figure 1.2). Which lysine residue 
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is methylated as well as the stoichiometry (mono, di or tri) of methylation at that 
lysine impact the transcriptional status of nearby genes and the functions of nearby 
regulatory DNA elements. For example, H3K4 monomethylation, H3K4me1, marks 
enhancer regulatory sequences. However, dimethylation and trimethylation of 
H3K4, H3K4me2, and H3K4me3 is associated with transcriptionally active 
promoters (18). Trimethylation at lysine 9 of H3, H3K9me3, is associated 
transcriptionally silent genes, highlighting the importance of the residue on which 
trimethylation occurs (19). Specific histone modifications occur concurrently at 
active and repressed gene promoters, consistent with the histone code hypothesis 
(Figure 1.3). So called “bivalent” histone signatures have also been described. 
These bivalent domains tend to be marked by activating H3K4me3 marks and 
repressive H3K27me3 marks and are considered “poised” for expression at 
specific developmental or differentiation time points. One recently described 
example is self renewing Thy1+ adult germline stem cells where the Sox2 
developmental gene is marked with H3K4me3 and repressive H3K27me3 marks 
as well as DNA methylation (20). These marks maintain Sox2 in a bivalent poised 
state, primed for activation, yet transcriptionally silent. How these bivalent regions 
are maintained and resolved remains an area of active inquiry. 
Despite extensive characterization of posttranslational modifications that 
occur on histones, how these marks work together and in isolation to coordinate 
transcriptional outcomes remains incompletely understood. One current 
hypothesis posits single histone modifications act as individual permission slips for 
specific transcriptional outcomes, with multiple permission slips being required for 
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outcomes to occur. This principle is observed for transcriptionally activating H3K4 
methylation carried out by the MLL family of histone methyltransferases. The 
presence of transcriptionally repressive H3K9 methyl marks on nearby histones 
deters MLL activity at H3K4. However, if H3K9 is acetylated, an activating mark, 
MLL activity is enhanced. 
Histone modifications carry out transcriptional responses through their 
ability to be read by histone mark readers. Histone readers have been identified 
for the majority of known histone marks (8). H3K4me3 marks, for instance, are 
read by a variety of protein domains, including chromo, PHD, and tudor domains 
(21). The ING family of proteins contain PHD domains and function within larger 
histone acetyltransferase complexes (21, 22). Additionally, CHD1, a 
transcriptionally activating ATP dependent chromatin remodeler, contains a 
chromodomain, which preferentially binds H3K4me3 marked histones (23). CHD1 
also interacts with basal transcription and preinitiation complex machinery to 
promote transcription of H3K4me3 marked genes (24). Similarly, acetylated 
histones are recognized by bromodomain containing proteins including TATA 
binding protein associated factors, histone acetyltransferases, and general 
transcription factors (25). This example of H3K4 trimethylation highlights how 







Posttranslational modification of transcription factors 
Modes and mechanisms of transcription factor  
posttranslational modification 
It is important to note that while histone mark readers are profoundly 
impactful on transcriptional outcomes, these readers lack sequence specific DNA 
binding capability and instead use histone marks to bind target regions in the 
genome. Furthermore, the enzymes that deposit histone marks, histone writers, 
also lack sequence specific DNA binding function. Therefore, how histone marks 
are precisely deposited and read at specific sequences within the genome remains 
an open question. Transcription factors are an obvious solution to this question, as 
they are capable of recognizing and binding specific DNA sequences. In fact, 
multiple reports have demonstrated transcription factors interact with chromatin 
modifiers at target genes (26). One such example is the epithelial to mesenchymal 
transition (EMT) transcription factor SNAIL. SNAIL directly interacts with the H3K9 
methyltransferase polycomb repressor complex proteins EZH2 and SUZ12 at the 
CDH1/E-cadherin gene promoter and these interactions are required for proper 
CDH1 repression during EMT (27). These reports highlight how transcription 
factors facilitate chromatin modifier recruitment to target genes, however, how 
transcription factors carry out these recruitment events remains largely unknown.  
Posttranslational modifications dynamically regulate protein functions, often 
by altering protein-protein interactions. As such, posttranslational modification is 
an appealing mechanism for how transcription factors interact with chromatin 
modifiers. Posttranslational modification of transcription factors would allow for 
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dynamic regulation of transcriptional states through regulated recruitment of 
specific chromatin modifiers. Indeed, an increasing number of transcription factors 
and other nonhistone proteins have been found to be posttranslationally modified 
(28-32).  
In fact, the number of nonhistone proteins subject to one such 
posttranslational modification, methylation, now far outnumber that of histone 
proteins. Curiously, nonhistone protein methylation appears to occur 
predominantly through the activity of methyltransferases originally identified for 
their histone methyltransferase activity. The H3K4 methyltransferase SETD7 
methylates at least 30 nonhistone proteins, 17 of which are transcription factors 
(30, 32). Similarly, the H3K9 methyltransferase G9a methylates at least 17 
nonhistone proteins, 7 of which are transcription factors  (30). Transcription factors 
methylated at lysines include: p53, RB, E2F1, TAF7, TAF10, PCAF, YAP, STAT3, 
FOXO3, GATA4, MTA1, C/EBPβ, MYOD, ERα, AR, KLF12, NFĸB, GLI3, and 
RARα (Figure 1.4 and Table 1.1) (30-33). Many transcription factors within this list 
are master regulators of cell fate, differentiation and survival, highlighting the 
importance of lysine methylation in transcription factor function.  
 
Examples of transcription factors regulated by  
lysine methylation 
One of the most well characterized examples of transcription factor lysine 
methylation is p53. p53 is methylated at lysines 370, 372, 373, and 382 by the 
methyltransferases SMYD2, SETD7, G9a, and SETD8, respectively (Table 1.1) 
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(34-36). SMYD2 mediated methylation at K370 corresponds with decreased p53 
DNA binding, decreased association with p53 effector 53BP1, and decreased p53 
dependent transcriptional and DNA damage responses (34, 37). Similarly, 
methylation at K373 is associated with inactive p53 (38). K370 methylation is 
antagonized by SETD7 mediated methylation at K372, which promotes p53 DNA 
binding and p53 mediated cell death responses (39). Antagonistic methylation at 
K370 and K372 is dynamically regulated by lysine specific demethylase 1, LSD1, 
which removes K370 methylation marks (40).  
Another master regulator transcription factor whose function is regulated by 
lysine methylation is RB. RB is methylated at K860 by SMYD2, which promotes 
RB interaction with the polycomb repressor complex protein L3MBTL1 (41). 
Similarly, methylation of RB at K873 by SETD7 promotes RB interaction with the 
heterochromatin protein HP1 (42).  
The examples of p53 and RB demonstrate discrete methylation events can 
alter protein-protein and transcriptional coregulator interactions for carrying out 
specific transcriptional and biological outcomes. At present, a relatively small 
subset of methyltransferases and demethylases have been found to regulate 
nonhistone protein methylation status. Predominantly, these methyltransferases 
are: SMYD2, SMYD3, SETD7, SETD8, G9a, Glp, and NSD1, while LSD1 is the 
only described nonhistone protein demethylase (Figure 1.4 and Table 1.1) (30-32). 
These findings suggest transcription factor posttranslational modification and 
specifically lysine methylation is a means to specifically recruit transcriptional 
coregulators and chromatin modifiers.  
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GFI1 as a paradigm for studying mechanisms of  
transcriptional control 
The GFI1 protein family 
Growth factor independence 1 (GFI1) is a repressive transcription factor 
with many important functions in normal and malignant hematopoiesis (43). GFI1 
was originally identified through an insertional Moloney murine leukemia virus 
(MMLV) screen where cloning of a provirus insertion site led to identification of the 
novel cDNA encoding a zinc finger containing protein, subsequently named GFI1 
(44). Proviral insertion resulting in GFI1 expression conferred IL-2 independent 
growth to the previously IL-2 dependent T-cell lymphoma cell lines 2780d and 
5675d (44).  
GFI1 is comprised of an N-terminal Snail/Slug/GFI1 (SNAG) domain, a C-
terminal concatemer of six C2H2-type zinc fingers and a linker region which 
separates them (Figure 1.5). GFI1 is the founding member of the GFI1 family, with 
the sole other member being GFI1B (45). GFI1 and GFI1B are highly conserved, 
with their SNAG domains sharing 95% amino acid identity (Figure 1.5) (46). The 
zinc fingers of GFI1 and GFI1B are also highly conserved, sharing 89% amino acid 
conservation (Figure 1.5). As such, both proteins bind a consensus DNA 
recognition motif with an AATC core recognition sequence (taAATCac(t/a)gca 
(43). GFI1 and GFI1B differ predominantly within their linker regions, which share 
only 39% conservation (Figure 1.5).  
Due to the large degree of conservation in their SNAG domains and zinc 
fingers, GFI1 and GFI1B exert similar, yet distinct molecular functions, due at least 
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in part to their cell type and tissue specific expression patterns (Figure 1.6) (47). 
GFI1B is expressed and functions predominantly in hematopoietic stem and 
multipotent progenitor cells as well as in megakaryocyte-erythrocyte progenitor 
cells (Figure 1.6) (43, 45). GFI1 is expressed and functions predominantly in 
hematopoietic stem cells, myeloid, and lymphoid primed multipotent progenitor 
cells (Figure 1.6) (43). 
The distinct hematologic functions of GFI1 and GFI1B are manifested 
physiologically in humans as well. Hereditary neutropenia due to GFI1 mutations 
has been reported in at least two families (48). Affected individuals are germline 
carriers of either an N382S or K403R mutation occurring within the fifth and sixth 
zinc fingers of GFI1, respectively. It is presumed, although remains to be 
functionally tested, that both mutations are dominant loss of function mutations 
owing to their ability to abolish DNA binding (N382S) or by interfering with cofactor 
binding (K403R) (43). It is also presumed the reported R421X, L400F, and P107A 
mutations give rise to neutropenia due to their ability to abolish DNA binding. One 
case of a neutropenic patient carrying a Q17 mutation within the SNAG domain 
has also been found (personal communication). To our knowledge, this is the only 
known mutation occurring in the SNAG domain that is associated with congenital 
neutropenia in humans. An S36N GFI1 mutation is observed in acute myeloid 
leukemia where it is thought to predispose patients through disrupting GFI1 
coregulator interactions (49, 50). Gfi1 null mice recapitulate the neutropenic 
phenotype observed in humans, in addition to displaying defects in pre-T-cell 
differentiation and impaired inner ear hair cell development (47, 51). These results 
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highlight the importance of Gfi1 in hematopoiesis and specifically within the 
lymphoid and myeloid compartments. 
Mutations in GFI1B have also been described clinically. A zinc finger 5 
protein truncating frameshift mutation of GFI1B that is unable to bind DNA is 
observed in a family with an inherited mild thrombocytopenia and red blood cell 
anisopoikilocytosis (43). A protein truncating dominant negative mutation occurring 
at residue Q287 within zinc finger 5 of GFI1B has also been described in a family 
with gray platelet syndrome. This mutation abolishes DNA binding by GFI1B, 
causing platelets to have decreased alpha granules and confers a moderate 
bleeding tendency and a moderate thrombocytopenia in carriers (52). Gfi1b null 
mice are embryonic lethal due to failure to produce enucleated erythrocytes (53). 
The fetal liver of Gfi1b null embryos also contains developmentally arrested 
erythroid and megakaryocytic precursors, highlighting the importance of  Gfi1b in 
erythrocyte and megakaryocyte cell lineage fate determination (53). Taken 
together the Gfi1 and Gfi1b human and mice phenotypes also demonstrate the 
distinct functions of GFI1 family members both inside and outside the 
hematopoietic compartment.  
 
GFI1 transcriptional coregulators 
 Clinical descriptions of loss of function mutations within the zinc fingers of 
GFI1 highlight the critical importance of DNA binding for GFI1 function. However, 
aside from the requirement for DNA binding, relatively little is known about how 
GFI1 functions as a transcriptional repressor. A variety of transcriptional 
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corepressors and histone modifying enzymes interact with GFI1 (Figure 1.5). 
Histone deacetylase complexes 1, 2, and 3 (HDAC 1-3) interact with the N-terminal 
portion of the GFI linker region. Euchromatic histone-lysine N-methyltransferase 2 
(G9a/EHMT2) binds GFI1 via contributions from both the N- and C- terminal 
portions of the GFI linker (54). Ajuba, an HDAC dependent transcriptional 
corepressor binds GFI1 through yet to be mapped regions of GFI1 (55). The 
activated Notch1-intracellular domain (N1-ICD) binds GFI1 within the C-terminal 
portion of the GFI1 linker (data unpublished). A variety of other transcription factors 
and transcriptional corepressors interact with GFI1 via the GFI1 linker and zinc 
fingers, including, MTG8, MTG16, ETS1, Miz1, and Pu.1 (Figure 1.5) (45, 56-58). 
Lysine specific demethylase 1 (LSD1/KDM1A) is a transcriptionally repressive 
mono and di H3K4 demethylase which binds GFI1 via the SNAG domain. LSD1 is 
the only protein known to bind the SNAG domain (Figure 1.5) (43).  
 
GFI1 requires the SNAG domain and zinc fingers  
for repression 
Initial characterization of GFI1 demonstrated at least two domains are 
required for GFI1 transcriptional repressor function, the SNAG domain, and zinc 
fingers. DNA binding via zinc fingers 3-5 is required for transcriptional repression 
by GFI1 (59). Furthermore, each zinc finger (3, 4, and 5) is required for DNA 
binding, as deletion of a single one of these zinc fingers abolishes repressor 
activity (59). In addition to zinc fingers, the N-terminal SNAG domain is required 
for transcriptional repression by GFI1 (59). The linker region of GFI1 is largely 
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dispensable for repressor function, as a linker deleted construct consisting of only 
the SNAG domain and zinc fingers 1-6 has comparable repression ability as full 
length wild-type GFI1 (59). Additionally, zinc fingers 1-6 alone are not capable of 
transcriptional repression (59). These data suggest the SNAG domain is the 
dominant repressive element within GFI1, and is localized to sites of repression 
through the function of the GFI1 zinc fingers.  
Individual residues within the SNAG domain are critical for GFI1 repressor 
function. A proline to alanine substitution at the 2 position (P2A) completely 
abolishes repressor function (59). Interestingly, alanine substitution at other SNAG 
domain positions does not impact repressor function, even at immediately adjacent 
positions, such as R3, S4, K10, and K11 (59). These findings demonstrate the 
SNAG domain is a critical determinant of GFI1 mediated transcriptional repression 
and suggests individual residues within the SNAG domain are required for this 
function.  
 
Putative GFI1 SNAG domain methylation  
Lysine 8 (K8) is a universally conserved residue across GFI1 family 
members as well as across human, mouse, fish, xenopus, dolphin, pig, dog, cat, 
horse, elephant, and guinea pig, among others (Figure 1.5). K8 resides within a 
KSKK motif embedded within the SNAG domain, occurring at residues 8 through 
11 (Figure 1.5). As described previously, p53 is subject to methylation, which 
dynamically regulates its function (36). Lysine methylation occurs at residues 
K370, K372, and K373 of p53, which reside within a KSKK motif identical to that 
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found within the GFI1 SNAG domain (35). Within this methylation dependent 
functional axis of p53, LSD1 specifically demethylates the first lysine, K370, of the 
p53 KSKK motif (40). LSD1 is also a known effector of GFI1 family mediated gene 
repression and the only protein known to bind the GFI1 SNAG domain (43, 46). 
From this, we speculated the KSKK motif embedded within the GFI1 SNAG 
domain may be a mechanism by which LSD1 binds the GFI1 SNAG domain. We 
focused on K8 within this motif, as LSD1 acts on the K8 equivalent residue, K370, 
in p53 and as alanine substitution at K10 and K11 does not impair repressor 
function (59). Additionally, alanine substitution at K8 abolished LSD1 interaction 
with this GFI1B isoform (60). LSD1 from UT-7 cell lysates also preferentially bound 
a K8 dimethylated Gfi1B SNAG domain peptide in vitro, suggesting methylation at 
K8 may be a critical determinant of LSD1 recruitment to the SNAG domain (60). 
 
GFI1 SUMOylation/ubiquitination 
Similar to methylation, ubiquitin, and small ubiquitin related modifier 
(SUMO) marks are a posttranslational modification covalently attached to target 
substrates to modulate their function (61, 62). Previous reports indicate GFI1 
interacts with the ubiquitin ligase Triad1 (63). However, the GFI1/Triad1 interaction 
was not mapped on either protein, nor was the site of ubiquitination identified, and 
counterintuitively the authors described Triad1 as prolonging cellular GFI1 half-life 
(63). Previous to our work, no evidence for GFI1 SUMOylation has been reported. 
Diverse cellular functions regulated by SUMOylation include, protein 
stability, subcellular and subnuclear localization, chromatin structure and 
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transcriptional regulation (62). SUMOylation of target protein substrates proceeds 
through coordinated activities of three SUMO machinery enzymes (61, 62). An E1 
SUMO activating enzyme coordinates transfer of the SUMO group to UBC9, an E2 
SUMO conjugating enzyme. In the final step, an E3 SUMO ligase coordinates E2 
and target protein specificity for the eventual transfer of the SUMO group to the 
target substrate (62). SUMO modification occurs at the ε-amine group of lysine 
residues and approximately 75% of SUMO modifications occur within a type I 
SUMO consensus element ψKx(D/E), where ψ is a large hydrophobic residue and 
x is any amino acid (64, 65).  
An increasing number of proteins, including transcription factors have been 
found to be regulated by SUMOylation (61, 62). Sharp-1 is a myogenic 
transcription factor that antagonizes MyoD activity (66). Sharp-1 is SUMOylated at 
K240 and K255, and these modifications are enhanced by the presence of PIAS3 
and PIASxα (66). SUMOylation defective Sharp-1 is impaired in transcriptional 
repression as well as MyoD antagonism and displays decreased binding to G9a, 
a methyltransferase that methylates K104 of MyoD (30, 66). These data 
demonstrate a key role for SUMOylation of Sharp-1 for G9a recruitment and 
inhibition of myogenic differentiation, presumably through MyoD. SOX10 is 
another transcription factor modified by SUMOylation. SUMOylation modulates 
SOX10 function through impairing interaction with SOX10 coactivators EGR2 and 
PAX3, thereby impairing SOX10 transcriptional activity (67). Similar to SOX10,  
SUMOylation of SOX6 impairs SOX6 transcriptional activity (68). These data 
demonstrate SUMOylation profoundly impacts transcription factor function, often 
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through augmenting interaction with transcriptional coregulators. 
We analyzed the primary sequence of GFI1 using SUMO prediction 
algorithms and found a type I SUMO consensus element (GVKVES) occurring at 
residues 237-242 in the GFI1 linker, where the underlined sequence is the core 
type I consensus sequence (Figure 1.5) (65, 69). Furthermore, PIAS3, an E3 
SUMO ligase binds the linker region of GFI1, where the type I SUMO consensus 
element centered around K239 occurs. (70). Given these published data, we 
hypothesized GFI1 may be subject to regulation by SUMOylation, likely within the 
linker region. 
 
Posttranslational modifications may regulate  
GFI1 functions 
During my thesis work I investigated how posttranslational modifications 
regulate GFI1 transcriptional repressor and cellular functions. Based on the 
previously published observations described above we focused on how putative 
SNAG domain methylation and linker region SUMOylation events modulate GFI1 
function. We find that GFI1 is regulated by methylation and SUMOylation and 
these posttranslational modifications regulate GFI1 function through augmenting 
LSD1/CoREST interaction. In Chapter 2, we show GFI1 is SUMOylated at K239 
by SUMO2/3, UBC9, and PIAS3 SUMO machinery. In Chapter 3, we show GFI1 
is methylated at K8 by SMYD2. We find these posttranslational modifications are 
required for GFI1 transcriptional repressor function and contribute to GFI1 
functions during primitive erythropoiesis in zebrafish as well as in GFI1 mediated 
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neutrophil differentiation and leukemia cell survival. Disruption of these 
modifications also impairs LSD1/CoREST binding, demonstrating the importance 
of LSD1/CoREST within this functional GFI1 axis. We propose SUMOylation and 
methylation are part of a dual input mechanism that regulates GFI1 function. These 
posttranslational modification dependent recruitment events then stabilize and 
activate LSD1 for H3K4 demethylation and repression of GFI1 target genes. 
The context, scope, and implications of these findings are discussed in 
Chapter 4. This includes the potential combinatorial regulation of lysine 
methylation within the GFI1 SNAG domain, as well as potential crosstalk between 
methylation and SUMOylation in GFI1. We also speculate about functional 
crosstalk between GFI1, p53, and other nonhistone proteins regulated by lysine 
methylation. Lastly, we assess the potential breadth of transcription factor 
posttranslational modifications in the human proteome and the applications and 
limitations of current methodologies to characterize these modifications and their 
functional consequences. Taken together, the work of my thesis provides novel 
mechanisms for how posttranslational modifications of GFI1 serve to repress GFI1 
target genes through LSD1/CoREST. My thesis work also contributes to the 
emerging understanding of how transcription factors interact with histone 
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Figure 1.1 Genomic DNA is subject to extensive packaging via nucleosomes. 
Levels of DNA compaction are illustrated. In order from least compact to most 
compact: DNA double helix, beads on a string, 30 nanometer fiber, extended 









Figure 1.2. A subset of lysine methylation and acetylation events occurring on 
lysines 4, 9, 27, and 36 of the histone H3 tail and the enzymes that write and erase 
these marks. The sequence of amino acids 1-40 for HIST1H3A is given. 
Methylation and demethylation events at lysine residues are depicted by dark red 
and light red boxes respectively. Acetylation and deacetylation events at lysine 
residues are depicted by dark blue and light blue boxes respectively. Enzymes 
with respective methylation/demethylation and acetylation/deacetylation activities 
are listed extended from their respective colored boxes. Specific mono (me1), di 
(me2) and tri (me3) methylation, demethylation and acetylation/deacetylation  








Figure 1.3. Histone code promoter marks frequently associated with 
transcriptional activation and repression outcomes. Histone marks are listed in 
boxes above area in which they are typically found relative to the gene transcription 
start site. The transcription start site is depicted by a line with a pointed arrow (for 
active transcription) or a flat line (for repressed transcription). Promoter marks 
associated with active transcription are listed in the top schematic while promoter 








Figure 1.4. Graphical representation of nonhistone proteins regulated by lysine 
methylation and the methyltransferases and demethylases that regulate 
methylation status of these proteins. Methylated proteins are shown as grey boxes 
with protein names above the boxes. GFI1 and p53 shown as black boxes. 
Methyltransferases and demethylases are shown as circles. LSD1 is the only 
demethylase shown, as it is the only demethylase known to regulate nonhistone 
protein methylation status. Lines connecting boxes and circles indicate the 









Figure 1.5. Graphical depiction of GFI1 protein domains and where GFI1 
interacting proteins bind within GFI1. GFI1 is comprised of an N-terminal SNAG 
domain, followed by a linker region and a C-terminal concatemer of six zinc fingers. 
Zinc fingers 3-5 are required for DNA binding. Various transcription factors, histone 
modifying enzymes and transcriptional coregulators and the regions within GFI1 
they bind are highlighted. * percentages below GFI1 domains denote percent 
residue identity between GFI1 and GFI1B. Primary protein sequence of the GFI1 
SNAG domain across species is given. A grey box designates a species conserved 
lysine-serine-lysine-lysine (KSKK) motif occurring at residues 8-11 in the GFI1 
SNAG domain. Residues surrounding a type I SUMO consensus element 










Figure 1.6. GFI1 and GFI1B contribute to distinct hematopoietic lineages. 
Respective colored areas for GFI1 and GFI1B indicate relative protein expression 
within the associated hematopoietic compartment as well as the functional 
contribution of GFI1 and GFI1B to this cell type and fate. Cell types are indicated 
by colored circles with the relative potential to contribute to each lineage indicated 
as a colored portion of the full circle. Cell type abbreviations are as follows. HSC 
– hematopoietic stem cell, LMPP – lymphoid primed multipotent progenitor, CLP – 
common lymphoid progenitor cell, EPLM – early progenitor with lymphoid and 
myeloid potential, B – B cell,  DN1 – double negative 1, DN2 – double negative 2, 
T – T cell, Gran – granulocyte, CMkE – common megakaryocyte erythrocyte 








Table 1.1. Abbreviated list of nonhistone proteins regulated by lysine 
methylation. 
Protein: Motif: Residue: Methyltransferase: Demethylase: 
p53 370KSKK373 K370 SMYD2 LSD1 
 370KSKK373 K372 SETD7   
 370KSKK373 K373 G9a 
Glp 
 
 379RHKK382 K382 SETD8  
RELA/p65 36YKCE39 K37 SETD7  
 217DKVQK221 K218 NSD1  
 217DKVQK221 K221 NSD1  
 310KSIMKK315 K310 Glp  
 310KSIMKK315 K314 SETD7  
 310KSIMKK315 K315 SETD7  
STAT3 137VTEKQ141 K140 SETD7 LSD1  
TAF10 186KSKD190 K189 SETD7  
TAF7  2KSKD6 K5 SETD7  
ERα 265LKHKR269 K266 SMYD2 LSD1 
 265LKHKR269 K268 SETD7 LSD1 
 299KRSKK303 K302 SETD7  
GLI3 433KRSKIK438 K436 SETD7  
 592DRAK595 K595 SETD7  
AR  631KLKK634 K632 SETD7  
PPP1R12A 439GLRK442 K432 SETD7 LSD1 
E2F1 182KKSK185 K185 SETD7 LSD1 
RB 809LKSPYK813 K810 SMYD2  
 858VLKR861 K860 SMYD2  
 870KPLKK874 K873 SETD7  
RARα 107GCKG110 K109   
 167KEVPK171 K171   
GATA4  298YMKL301 K300 EZH2  
MYOD 99KACKRK104 K104 G9a  
FOXO3  268AKKKA272 K270 SETD7  
 268AKKKA272 K271 SETD7  
KLF12 311SRKR314 K313 G9a  
IRF1 124KSKS128 K126 SETD7  
NR1H4  204KSKR207 K206 SETD7  
MTA1 530VRKP533 K532 G9a  
MEF2D  265SRKP268 K267 G9a  
HSP90 207VKKH210 K209 SMYD2  
PCNA 247LKYY250 K248 SETD8  















SUMOYLATION REGULATES GROWTH FACTOR INDEPENDENCE 
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GFI1 FUNCTIONS IN TRANSCRIPTIONAL CONTROL  
AND CELL FATE DETERMINATION REQUIRE  





Proper hematopoietic cell fate decisions require coordinated functions of 
transcription factors, their associated coregulators, and histone modifying 
enzymes. Growth factor independence 1 (GFI1) is a zinc finger transcriptional 
repressor and master regulator of normal and malignant hematopoiesis. While 
several GFI1 interacting proteins have been described, how GFI1 leverages these 
relationships to carry out transcriptional repression remains unclear. Here we 
describe a functional axis involving GFI1, SMYD2, and LSD1 that is a critical 
contributor to GFI1 mediated transcriptional repression. SMYD2 methylates lysine-
8 (K8) within a -8KSKK11- motif embedded in the GFI1 SNAG domain. Methylation 
defective GFI1 SNAG domain lacks repressor function due to failure of LSD1 
recruitment and persistence of promoter H3K4 dimethyl marks. Methylation 
defective GFI1 also fails to complement GFI1 depletion phenotypes in developing 
zebrafish and lacks progrowth and survival functions in lymphoid leukemia cells. 
Our data show a discrete methylation event in the GFI1 SNAG domain that 
facilitates recruitment of LSD1 to enable transcriptional repression and coordinate 
control of hematopoietic cell fate in both normal and malignant settings. 
 
Introduction 
Growth factor independence 1 (GFI1) is a transcriptional repressor and 
master regulator of normal and malignant hematopoiesis. GFI1 is comprised of a 
20 amino acid N-terminal Snail/GFI1 (SNAG) domain, a C-terminal concatemer of 
six C2H2-type zinc fingers and a linker region that separates them (1). GFI1 
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mediated transcriptional repression requires DNA binding via zinc fingers 3, 4, and 
5 (2). The SNAG domain is the dominant contributor to transcriptional repression 
by GFI1 (2). GFI1 and its paralog, GFI1B, share 95% identity within their SNAG 
domains and have a high degree of conservation within their zinc fingers (3). This 
conservation is reflected by their recognition of a common response element 
[TAAATCAC(A/T)GCA; response element in bold face] and shared binding 
partners, yet knock in experiments in mice show GFI1 and GFI1B only partially 
substitute for one another in hematopoietic development (4). 
GFI1 contributes to hematopoietic stem cell (HSC) quiescence and self 
renewal (5, 6). GFI1 is also an obligate transcription factor in granulopoiesis and 
is equally critical to establish and maintain lymphoid fate in development of the 
adaptive immune system (3, 7). Mutations (N382S, K403R) within GFI1 zinc 
fingers act in a dominant negative fashion to cause severe congenital neutropenia 
(SCN) (8, 9). In the malignant setting, GFI1 is required to establish and maintain 
lymphoid leukemia/lymphoma, at least, in part, by restricting proapoptotic functions 
of p53 (10-12). These reports highlight the critical roles filled by GFI1 in both 
normal and malignant hematopoiesis.  
GFI1 functions through discrete interactions with partner DNA binding 
proteins, transcriptional coregulators, and histone modifying enzymes, including 
ETS1, MTG8, MTG16, G9a, HDAC1, and LSD1 (13-16). Factors influencing GFI1 
interactions with these partners to govern transcriptional repression are 
incompletely understood. By virtue of its demethylase activity toward mono and/or 
dimethylated histone H3, lysine 4 (H3K4me1/me2), LSD1 is the dominant effector 
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for GFI1 mediated transcriptional repression and is the only protein known to bind 
the SNAG domain in either GFI1 or GFI1B (1). A single amino acid substitution 
from proline to alanine at residue 2 (P2A) within the SNAG domain profoundly 
impairs LSD1 binding and GFI1 repressor function (2). Likewise, disruption of 
LSD1 binding to the GFI1B SNAG domain impairs GFI1B mediated gene 
repression and disrupts proper erythroid and megakaryocytic differentiation (14). 
Notably, substitutions at nearby residues (R3A, S4A, K10A, and K11A) have 
minimal impact on GFI1 repressor function (2). These data suggest residue 
specific impact upon LSD1 binding and GFI1 function via the SNAG domain, yet 
leaves as an open question how this impact is established and whether GFI1-LSD1 
binding and repressor functions might be regulated via modifications at these 
residues.  
The SNAG domain in GFI1 contains a family and species conserved lysine-
serine-lysine-lysine (KSKK) motif occurring at residues 8 through 11 (14). Over 
300 UniProt genes encode a KSKK motif, including one occurring from residues 
370 to 373 in p53. Residue specific lysine methylation in the p53 -370KSKK373- 
motif, catalyzed by protein lysine methyltransferases SMYD2, SETD7, G9a and 
Glp, dynamically regulate p53 function (17-20). From this, we hypothesized the 
GFI1 -8KSKK11- motif may be similarly regulated by methylation, and given 
functional connections between GFI1 and p53, that the same methyltransferases 
may govern GFI1 transcriptional repression function attributable to SNAG—LSD1 
binding. We show that SMYD2 binds and methylates K8 within the GFI1 SNAG 
domain to promote its interaction with LSD1. Leucine substitution at K8 (K8L) 
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abolishes LSD1 binding required for transcriptional repression by the SNAG 
domain in isolation. Likewise, GFI1-K8L fails to complement the defect in zebrafish 
primitive erythropoiesis brought on by gfi1aa depletion and is unable to support T-
ALL cell survival after depletion of endogenously expressed GFI1. These data 
indicate that SNAG domain methylation governs GFI1—LSD1 axis functions and 
when considered with other GFI1 posttranslational modifications, may be one of 
several regulatory inputs to this critical determinant of hematopoietic cell fate 
decisions. 
 
Materials and methods 
Reagents and antibodies  
Mouse monoclonal α-FLAG (M2) and α-tubulin (B-5-1-2) antibodies were 
obtained from Sigma Aldrich. Rabbit polyclonal α-myc (A-14) and goat polyclonal 
α-GFI1 (sc-8558, N-20) antibodies were obtained from Santa Cruz Biotechnology. 
Rabbit polyclonal α-H3 (ab1791) and rabbit monoclonal α-H3K4me2 (ab32356) 
antibodies were obtained from Abcam. Rabbit monoclonal α-LSD1 (C69G12, 
#2184) antibody was obtained from Cell Signaling Technology. Horseradish 
peroxidase (HRP) conjugated α-mouse, α-rabbit, and α-goat IgG were obtained 
from Jackson Immunoresearch. LSD1 inhibitor, HCI-2509, has been described 
previously (21). Restriction endonucleases, polymerases, and ligases were 





Plasmids and subcloning  
GFI1:3X-FLAG constructs were a generous gift from Dr. Tarik Moroy (22). 
P2A and K8L substitutions were generated by two-stage PCR and splicing by 
overlap extension. GFI1 SNAG domain derivative fusion proteins with the Gal4 
DNA binding domain were generated by first annealing complementary single 
stranded DNA oligonucleotides encoding SNAG domain derivative sense and 
antisense strands. The sense strand incorporated an EcoRI site at its 5’ end while 
the antisense strand contained a MluI site at its 5’ end. Annealed oligonucleotides 
encoding SNAG domain derivatives were restricted with EcoRI/MluI and 
subcloned into EcoRI/MluI restricted pCMV5. The Gal4 DNA binding domain 
sequence (encoding amino acid residues 1-147) was inserted in-frame and 3’ of 
the respective SNAG domain derivative using XbaI/BamHI restriction sites. LSD1 
constructs have been previously described (23). Complete open-reading frame 
sequences for all constructs were confirmed by automated dideoxy sequencing in 
the University of Utah Health Sciences DNA Sequencing Core Facility. Primer 
sequences used to generate constructs are provided in the supplemental material.  
 
Cell lines and culture 
Cos7L cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% FBS, GlutaMAX, and pen-strep. CCRF-CEM 
cells were maintained in RPMI-1640 media supplemented with 10% FBS, 
GlutaMAX and pen-strep. Gal4-UAS-TK-Luc HEK 293T-Rex cells (referred to as 
HEK293 reporter cells throughout the text) were generously provided by Raphael 
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Margueron of the Institut Curie- Unité de Génétique et de Biologie du 
Développement, Paris, France, and maintained in DMEM supplemented with 10% 
FBS, GlutaMAX and pen-strep. 
 
Luciferase assays 
Luciferase assays were performed using a dual luciferase assay kit 
according to manufacturer protocols (Promega). Briefly, 3.25 x 105 Gal4-UAS-TK-
Luc HEK 293T-Rex cells were seeded per well in 6-well plates. Transfection of 
plasmids expressing SNAG:Gal4 derivatives and additional plasmids shown in 
figures was performed in triplicate using Lipofectamine 2000 according to 
manufacturer protocols. Reporter activity was measured in cell lysates collected 
between 24 and 48 h posttransfection. Firefly luciferase activity was normalized to 
a constitutive, cotransfected Renilla luciferase control. Statistical significance was 
determined by two-sided unpaired t-tests (P-values, * <0.05, ** <0.005, *** 
<0.0005, **** <0.00005). 
 
ChIP-qPCR  
Briefly, transfection of Gal4-UAS-TK-Luc HEK293 T-Rex cells was 
performed using Lipofectamine 2000 according to manufacturer protocols. 48 h 
posttransfection cells were crosslinked in 1% formaldehyde for 15 min at room 
temperature. Crosslinking was terminated with 125mM glycine for 5 min at room 
temperature. Cells were washed with ice cold PBS and lysed in ice cold Farnham 
lysis buffer (24, 25). Cell lysates were sonicated at 5 watts for 5 s on, 25 s off 
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intervals for a total of 1 min and 30 s. Antibody coated Dynabeads (Thermo Fisher 
Scientific) were added to clarified lysates and incubated at 4C overnight. Beads 
were washed three times with LiCl buffer (100mM Tris, 500mM LiCl, 1% NP-40, 
1% sodium deoxycholate, pH 7.5) followed by a single wash in TE buffer (10mM 
Tris, 1mM EDTA, pH 8.0). Crosslinks were reversed in IP elution buffer (100mM 
NaHCO3, 1% SDS) at 65C overnight. Immunoprecipitated DNA was recovered 
using ChIP DNA Clean and Concentrator (Zymo Research) and quantified using 
the PicoGreen system (Thermo Fisher Scientific). PCR was performed using the 
Luc-TSS-FWD and Luc-TSS-REV primers (see supplemental information). Fold 
enrichment was determined by the Ct method and normalized to input DNA. All 
qPCR reactions were performed in triplicate using SsoFast EvaGreen Supermix 
reagent (Bio-Rad). 
 
Zebrafish morpholino and mRNA injections  
Zebrafish were maintained in the aquatics shared resource at the Huntsman 
Cancer Institute. Morpholinos were purchased from Gene Tools, LLC. mRNAs 
were generated using mMessage mMachine T7 transcription reactions (Ambion, 
Thermo Fischer). Embryos were microinjected at the 1 cell stage with 1 nl of 20 
µM splice blocking gfi1aa and 200 µM kdm1a morpholino with 10% phenol red and 
sterile water. mRNAs were coinjected with morpholino at a final concentration of 
100 ng/µl. Unspliced gfi1aa mRNA was detected in gfi1aa morpholino injected 
embryos by PCR amplification of the morpholino targeting intron 1/exon 2 
boundary within cDNA preparations as described previously (26). Morpholino and 
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primer sequences are provided in supplemental materials. Dechorionated, 48 h 
postfertilization (hpf) embryos were stained in a solution of 40% ethanol, 0.65% 
H2O2, 0.01M sodium acetate, 0.6mg/ml o-dianisidine in the dark on a rolling 
rotisserie for 2 h. Embryos were thoroughly washed with PBS-T and visualized on 
a dissecting microscope. Primitive erythropoiesis was quantified using a scoring 
system from 1 to 4, indicating minimal (1), modest (2), moderate (3), and complete 
(4) hemoglobinization as revealed by o-dianisidine staining. More than 60 embryos 
were scored for each experimental condition. Statistical significance was 
determined by Wilcoxon-Mann-Whitney testing in GraphPad Prism 6 (P-values, * 
<0.05, ** <0.005, *** <0.0005, **** <0.00005). 
 
Transfection, immunoprecipitation, and drug treatments  
Cos7L cells were transfected using Lipofectamine 2000 (Life Technologies) 
as previously described (26). Cell lysates were harvested in phospho protecting 
lysis buffer (PPLB) 48 h posttransfection and immunoprecipitation performed from 
clarified cell lysates using α-FLAG (M2) antibody and Protein G Sepharose beads 
(26). Immune complexes and clarified lysates were probed using antibodies 
indicated in the figures and figure legends. SMYD2 inhibitor, LLY-507, was 
prepared in DMSO and dosed as indicated (27). The LSD1 inhibitor, HCI-2509, 






In vitro peptide binding  
GFI1 SNAG domain peptides were synthesized by GenScript to > 95% 
purity and conjugated to biotin. SNAG domain peptides were incubated at 4C with 
purified human recombinant LSD1 or extracts prepared from CCRF-CEM cells 
under nondenaturing conditions. Biotinylated peptides and bound LSD1 were 
isolated using streptavidin agarose beads (Thermo Fisher Scientific), washed 
extensively in incubation buffer (50mM HEPES, pH 7.5) and subjected to α-LSD1 
western blotting as described above. 
 
Methyltransferase assays  
GFI1 SNAG domain peptides were incubated with human recombinant 
SMYD2 (Cayman Chemical) and 3H-S-adenosylmethionine (SAM) at 30°C. 
Biotinylated peptide substrates were purified from reaction mixtures using 
streptavidin agarose beads (Thermo Fisher Scientific). Beads were washed 
extensively with reaction buffer, resuspended in scintillation cocktail and 3H 
incorporation measured using a Beckman Coulter LS 6500 liquid scintillation 
counter. Statistical significance was determined by two-sided unpaired t-tests (P-
values, * <0.05, ** <0.005, *** <0.0005, **** <0.00005). 
 
shRNA and flow cytometry  
GFI1 depletion was achieved in cell lines via an shRNA targeting the 3’ UTR 
of GFI1 subcloned into the pMKO1 vector (a generous gift of Dr. Stephen 
Lessnick), relative to content matched scramble control. Selection was performed 
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in growth medium containing 3µg/ml puromycin for 3 days. Apoptosis in stable 
cells was determined by annexin V/propidium iodide (PI) staining on a FACSCanto 
Analyzer (BD). 
 
RNA sequencing  
Transcriptome RNA sequencing was performed as follows. Total RNA from 
4 biological replicates for each experimental condition was isolated using the 
Qiagen RNeasy Mini Kit with on column DNAse treatment. RNA quality was 
confirmed by RNA integrity number scoring on the Agilent RNA ScreenTape 
Assay. The Illumina TruSeq Stranded Total RNA Sample Prep Kit with Ribo-Zero 
Gold was used for sequencing library preparation. Illumina HiSeq 50 Cycle Single-
Read Sequencing version 4 sequencing protocol was performed and reads were 
aligned to the hg38 human genome assembly. Differentially expressed genes were 
identified at a greater than 2 fold change threshold and an adjusted P-value of 0.01 
relative to vector control CCRF-CEM cells. 
 
Results 
SNAG K8 methylation by SMYD2 promotes LSD1 binding  
and GFI1 mediated transcriptional repression 
Transcriptional repression by GFI1 can be predominantly attributed to LSD1 
recruitment by the SNAG domain (1). To gain additional insights into determinants 
of LSD1 binding, we examined the primary structure of GFI family proteins to find 
near complete conservation of a -8KSKK11- motif embedded within the SNAG 
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domains of GFI1 and GFI1B among diverse species (Figure 3.1). An analogous 
motif in p53 is subject to methylation by specific methyltransferases to dynamically 
regulate p53 function. We hypothesized methylation on -8KSKK11- lysine residues 
may similarly impact functions of the GFI1 SNAG domain.  
To test the contribution of -8KSKK11- motif residues to GFI1 mediated 
transcriptional repression we utilized a cell based, heterologous transcriptional 
reporter stably integrated into the host cell genome and regulated by a concatemer 
of five Gal4–UAS elements juxtaposed to an HSV thymidine kinase (TK) minimal 
promoter (Figure 3.1) (29). This system enables transcriptional output to be 
attributed specifically to motifs in GFI1 incorporated into fusion proteins with Gal4, 
free from partnerships GFI1 might have with other DNA binding proteins on an 
endogenous promoter. Likewise, the system permits transcriptional output to be 
measured in a chromatinized context and for assessment of promoter occupancy 
and histone modifications to be made in a unified fashion. When fused to the Gal4 
DNA binding domain, wild type (WT) SNAG or derivatives with discrete mutations 
can be examined for impact upon transcription, LSD1 recruitment and H3K4 
methylation status. We generated WT, K8L, K10L, and K11L SNAG:Gal4 fusion 
proteins (Figure 3.1) and tested their impact on transcriptional output from the 
integrated reporter. The SNAG domain alone, fused to Gal4, was sufficient to 
repress reporter output comparable to a GFI1-WT:Gal4 fusion protein lacking zinc 
fingers 4-6 (Figure 3.1 and data not shown), confirming a dominant role for the 
SNAG domain in GFI1 mediated transcriptional repression. Leucine substitution at 
K8 impaired repressor function, quantitatively similar to that observed with P2A 
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substitution (Figure 3.1) (2). Leucine substitution at either K10 or K11 had little 
impact on repressor function (Figure 3.1).  
LSD1 is the dominant effector of GFI1 mediated transcriptional repression 
and directly binds the GFI1 SNAG domain (1). To test whether the transcriptional 
repression defect of the K8L derivative reflected impaired LSD1 binding, we 
expressed FLAG-tagged WT, K8L, P2A, and SNAG derivatives of GFI1 in Cos7L 
cells and determined their ability to engage endogenously expressed LSD1 in -
FLAG coprecipitation assays. K8L substitution abolished the interaction between 
GFI1 and LSD1, comparable to SNAG domain deletion or P2A substitution (Figure 
3.1). These results indicate the GFI1 SNAG domain alone is sufficient for 
transcriptional repression, and by supporting LSD1 recruitment, K8 is essential to 
this function of the SNAG domain.  
We then tested whether methyltransferases, SMYD2, SETD7, and G9a 
influence SNAG domain mediated transcriptional repression. Methyltransferases 
were coexpressed with SNAG-WT:Gal4 and reporter activity quantified. SMYD2 
coexpression enhanced repression by SNAG-WT:Gal4, while SETD7 and G9a 
coexpression had minimal impact (Figure 3.2). Given the functional relationship 
between SMYD2 and transcriptional repression, we asked whether SMYD2 bound 
the SNAG domain. FLAG-tagged SMYD2 was transiently expressed alongside 
Gal4-tagged WT and K8L SNAG domains. Gal4 western blot of FLAG-immune 
complexes revealed an equivalent interaction between SMYD2 and both WT and 
K8L SNAG domains (Figure 3.2). We then tested SMYD2 methyltransferase 
activity towards GFI1 SNAG peptide either without or with the K8L substitution 
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(Figure 3.2). WT or K8L SNAG peptides were incubated with recombinant SMYD2 
and 3H-SAM. SNAG peptides were purified via their biotin tag and methylation 
measured by scintillation counting. K8 substitution significantly reduced activity of 
SMYD2 toward the SNAG domain, suggesting K8 is a SMYD2 methyl acceptor 
residue in GFI1. To test whether K8 is required for enhanced repressor function 
conferred by SMYD2, we expressed WT or K8L SNAG:Gal4 alongside SMYD2 
using the integrated reporter system. SNAG-K8L:Gal4 was insensitive to additional 
repression by SMYD2 (Figure 3.2). Likewise, an inhibitor of SMYD2, LLY-507, 
caused concentration dependent reversal of repression only for SNAG-WT but not 
for its K8L variant (Figure 3.2 and data not shown) (27). These data suggest 
SMYD2 contributes to GFI1 mediated transcriptional repression via methylation of 
K8 within the SNAG domain. 
 
SNAG domain K8 methylation recruits LSD1 for  
H3K4 demethylation and gene repression 
SMYD2 binds and methylates the GFI1 SNAG domain at K8 and contributes 
to GFI1 repressor function. To address directly the role of K8 methylation for 
SNAG—LSD1 binding, we synthesized biotinylated SNAG peptide dimethylated 
on K8 (SNAG-K8me2) then compared its interaction with LSD1 to that of 
unmethylated SNAG peptide. Recombinant human LSD1 (hLSD1) and CCRF-
CEM cell lysates containing LSD1 were incubated with biotinylated SNAG or 
SNAG-K8me2 peptides, then copurified on streptavidin conjugated beads. SNAG-
K8me2 peptide extracts hLSD1 from solution quantitatively while unmethylated 
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SNAG peptide bound only a small minority of the hLSD1 available, leaving >90% 
in solution (Figure 3.3). Similarly, the SNAG—LSD1 interaction was nearly 
undetectable using unmethylated SNAG peptide and CCRF-CEM extracts, while 
LSD1 binding increased dramatically using SNAG-K8me2 peptide (Figure 3.3). 
These findings indicate that K8 methylation strongly favors SNAG—LSD1 binding.  
To clarify LSD1’s contribution to GFI1 transcriptional repression in the 
integrated reporter system, LSD1 was coexpressed alongside SNAG-WT:Gal4 
and reporter activity quantified. Enforced LSD1 expression enhances 
transcriptional repression by SNAG-WT:Gal4 with no discernible impact on SNAG-
K8L:Gal4 (Figure 3.4 and data not shown). Expression of a catalytically inactive 
LSD1 derivative (K661A) reverses the enhanced repression conferred by WT 
LSD1 expression (Figure 3.4) while an LSD1 inhibitor, HCI-2509, causes 
concentration dependent reversal of repression by SNAG-WT:Gal4 but not SNAG-
K8L:Gal4 (Figure 3.4 and data not shown) (28). We then used chromatin immune 
precipitation and quantitative PCR (ChIP-qPCR) to investigate how loss of K8 
methylation might impact LSD1 recruitment and H3K4me2 status, and to correlate 
with transcriptional output from the integrated reporter system. ChIP-qPCR 
revealed WT and K8L SNAG:Gal4 equivalently bind the reporter promoter (Figure 
3.4). However, K8L substitution profoundly reduced LSD1 occupancy compared 
to SNAG-WT:Gal4 (Figure 3.4) and resulted in enrichment of H3K4me2 marks at 
the promoter locus (Figure 3.4). Combined, these data indicate K8 methylation 
strongly favors LSD1 recruitment by the SNAG domain to direct H3K4 
demethylation and to bring about transcriptional repression.  
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K8 methylation contributes to GFI1 function  
during developmental erythropoiesis 
GFI1 contributes to early myelo and lymphopoiesis in mice and humans (3). 
In the developing zebrafish, the GFI1 homolog, gfi1aa, is required for primitive 
erythropoiesis (30). We leveraged this functional requirement to test the 
importance of GFI1 K8 methylation in vivo. Hemoglobinized primitive erythrocytes 
in zebrafish were visualized by whole mount o-dianisidine staining at 48 h 
postfertilization (Figure 3.5). Embryo staining was scored across a numeric 
continuum representing minimal to complete erythropoiesis (26). Consistent with 
previous reports, morpholino mediated depletion of gfi1aa impairs primitive 
erythropoiesis and this defect could be complemented by coinjection of morpholino 
resistant mRNA encoding WT rat Gfi1 (Figure 3.5) (26, 30). However, coinjection 
of Gfi1 K8L mRNA failed to complement erythropoiesis defects brought on gfi1aa 
depletion, just as was observed using mRNA for the LSD1 binding deficient 
mutant, Gfi1 P2A. Notably, morpholino mediated depletion of the zebrafish LSD1 
homolog, kdm1a, phenocopies the defect in primitive erythropoiesis shown for 
gfi1aa depletion. This phenotype was reversed by coinjection of wild type human 
LSD1 mRNA (Figure 3.5). These data highlight the critical importance K8 
dependent GFI1—LSD1 binding to a GFI1 driven outcome in developmental 






K8 methylation is required for GFI1 progrowth and  
survival functions in lymphoid leukemia cells 
GFI1 is critical for the initiation and maintenance of lymphoblastic leukemia 
(11). GFI1 conditional deletion impedes lymphoma development in animal models 
and causes regression of established lymphomas (12, 31). We tested the 
importance of K8 for progrowth and survival functions of GFI1 in lymphoid 
leukemia cells. Using a GFI1 targeted shRNA, we depleted GFI1 in the 
lymphoblastic leukemia cell line, CCRF-CEM (Figure 3.6) and determined 
apoptosis relative to a content matched vector control (Figure 3.6). Apoptosis was 
determined by flow cytometry using concurrent propidium iodide (PI) and annexin 
V staining. Control cells display size and complexity features consistent with 
lymphocytes. A limited subset of cells underwent apoptosis (27% annexin V+/PI-). 
Following GFI1 depletion, the lymphocyte population displayed increased 
apoptosis (62% annexin V+/PI-) and a population with small size and widely 
divergent side scatter emerged. This emergent population, which increased with 
time following GFI1 depletion, is consistent with secondary necrosis (98% annexin 
V+/PI+) (Figure 3.6). Quantifying both apoptotic and secondarily necrotic 
populations reveals that GFI1 is required for CCRF-CEM cell survival (Figure 3.6). 
To determine the impact of K8 methylation and LSD1 recruitment on cell 
survival, we determined cell viability in stable CCRF-CEM cell lines expressing 
FLAG-tagged WT, P2A, and K8L GFI1 derivatives or vector control and 
simultaneously depleted of endogenous GFI1. We confirmed shRNA mediated 
depletion of endogenous GFI1 and enforced expression of FLAG tagged GFI1 
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derivatives by western blot (Figure 3.7). Cell lines depleted of endogenous GFI1 
then reexpressing wild type GFI1 retained growth potential, while those expressing 
P2A, K8L, or vector control failed to expand (Figure 3.7). These data indicate GFI1 
derivatives with defective LSD1 binding cannot functionally compensate for GFI1 
loss and suggest that K8 methylation may be a critical determinant of lymphoid 
leukemia cell viability. 
Total RNA from these cell lines was subjected to RNA sequencing. 
Clustering provided a list of genes upregulated with endogenous GFI1 depletion 
alone and in GFI1 depleted cells expressing WT, K8L, and P2A GFI1 derivatives 
(Figure 3.7). Genes upregulated following endogenous GFI1 depletion alone, as 
well as in GFI1 depleted cells expressing K8L and P2A GFI1 derivatives, but not 
WT GFI1 were subjected to gene ontology (GO) functional term enrichment (Figure 
3.7). This list was enriched for genes associated with programmed cell 
death/regulation of apoptosis and for loss of transcriptional repression (Figure 3.7). 
These results suggest K8 methylation is a critical determinant of LSD1 recruitment 




GFI1 is a transcriptional repressor and master regulator of cell fate, 
differentiation and survival in normal and malignant hematopoiesis (1). The N-
terminal SNAG domain is the dominant repressor element within GFI1. Yet, a 
detailed understanding of mechanisms governing transcriptional control by GFI1 
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is lacking (1, 32). We focused on the SNAG domain, and a -8KSKK11- motif 
embedded within the SNAG domain to gain additional mechanistic insights into 
GFI1 mediated transcriptional repression. We find SMYD2 methylates K8 within 
the SNAG domain, that K8 methylation favors LSD1 recruitment and that this 
SNAG—LSD1 relationship is required for GFI1—LSD1 axis functions in 
transcriptional repression and hematopoietic cell fate determination.  
Nonhistone proteins, including transcription factors, are subject to lysine 
methylation. Among them are p53, RB, E2F1, STAT3, MYOD, RELA/p65, AR, 
ERα, and CEBPβ (33-35). These factors play critical regulatory functions in cell 
growth and survival, and likewise instruct the establishment and maintenance of 
the differentiated state. Thus, lysine methylation occupies a central nexus for cell 
fate determination, making its coordinate control mechanisms among transcription 
factors essential for normal homeostasis. A growing roster of methyltransferases 
is responsible for lysine methylation among nonhistone proteins and transcriptional 
regulators, including SETD7, G9a, NSD2, SETD6, SMYD2, and SMYD3 (33-35). 
Often the methylation events catalyzed by these enzymes can be reversed by the 
methyl lysine specific demethylase, LSD1 (33, 35). The mechanistic and molecular 
consequences of lysine methylation vary for each transcription factor, and perhaps 
for each methylation event and stoichiometry. For example, RB is methylated at 
K860 by SMYD2, promoting its interaction with Polycomb group repressor protein 
L3MBTL1 and correlating with cell cycle arrest (36). However, RB can also be 
methylated at K873 by SETD7, which promotes RB’s interaction with the 
heterochromatin protein, HP1, and supports transcriptional repression, cell cycle 
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arrest, and myogenic differentiation (37). These examples demonstrate discrete 
methylation events that alter protein—protein and transcriptional coregulator 
interactions to carry out specific transcriptional and biological outcomes. This same 
principle is reflected in our description of the SMYD2—GFI1—LSD1 functional 
axis. SMYD2 methylates K8 to favor LSD1 binding. K8L substitution abolishes 
binding between GFI1 and LSD1, profoundly impairs transcriptional repression by 
the SNAG domain and renders GFI1 inactive in hematopoietic complementation 
and growth control. Yet, neither K10L nor K11L substitutions impact these 
phenotypes, suggesting a measure of residue selectivity in controlling GFI1 
function. Further studies will be needed to determine if K8 methylation within the -
8KSKK11- motif of GFI1’s SNAG domain alone governs LSD1 recruitment, or if 
instead, it is one of many methyl group modifications via distinct 
methyltransferases that are integrated to modulate transcriptional repression. 
Given that SMYD2 is a common regulator for GFI1 and p53, and that GFI1 exerts 
dominion over p53 DNA damage and proapoptotic responses, it is attractive to 
speculate that other p53 -370KSKK373- methyltransferases might modify analogous 
lysine residues in the GFI1 -8KSKK11- motif to achieve coordinate control over their 
counter regulatory relationship. Functional grouping of methyltransferases and 
demethylases toward transcription factor pairs has obvious advantages when 
minimizing regulatory complexity is a goal. We are actively pursuing this notion of 
shared regulatory factors for GFI1 and its transcriptional partners. 
Our findings add to an emerging choreography of posttranslational 
modifications that regulate GFI1 function and provide an example for how 
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coincident regulatory inputs may restrict the activity of an epigenetic effector like 
LSD1. We recently described a role for GFI1 SUMOylation in recruiting the 
LSD1/CoREST complex to GFI1 regulated promoters (26). We envisioned LSD1 
recruitment via the GFI1 SNAG domain could be stabilized, and its demethylase 
activity stimulated by interactions between CoREST and SUMOylated GFI1. Thus, 
SUMOylation provides one regulatory input for LSD1 activity when recruited to 
GFI1 regulated genes via the SNAG domain. Our finding that K8 methylation 
strongly favors, and K8L substitution abolishes LSD1 binding, GFI1 mediated 
transcriptional repression and cell fate decisions suggests a second regulatory 
input for the GFI1—LSD1 axis. Our data support a working model for 
transcriptional control via the SMYD2—GFI1—LSD1 axis (Figure 3.8) where 
transcriptional repression by GFI1 is favored by concurrent, SMYD2 mediated K8 
methylation and SUMOylation within the GFI1 linker, together facilitating 
LSD1/CoREST recruitment and enabling CoREST dependent activation of LSD1 
demethylase activity at target genes (26). Future work will clarify how these and 
other posttranslational modifications regulate GFI1 transcriptional control to 
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Figure 3.1. Lysine 8 contributes to transcriptional repression by the GFI1 SNAG 
domain. A. Primary protein sequence conservation of the GFI1 and GFI1B SNAG 
domains across species, compared to human GFI1. The conserved KSKK motif 
between residues 8-11 is shown. Sequence around the KSKK motif in human p53 
is shown for comparison. B. Graphical depiction of HEK293 T-REx heterologous 
transcriptional reporter. A stably integrated luciferase reporter is expressed under 
the control of a thymidine kinase (TK) minimal promoter immediately downstream 
of five Gal4-UAS elements. Structure of fusion proteins, comprised of wild type 
(WT) or KL derivative SNAG domains (as shown) and the Gal4 DNA binding 
domain, residues 1-147, are shown. C. Impact of SNAG domain single amino acid 
substitutions on integrated luciferase reporter activity. HEK293 reporter cells were 
transiently transfected with SNAG:Gal4 fusion proteins. Firefly luciferase output 
was determined using a dual luciferase assay kit with firefly luciferase values 
normalized to a Renilla luciferase transfection control. Results are expressed as 
mean +/- SD from a representative experiment performed in triplicate. D. Impact 
of GFI1-K8L substitution on GFI1—LSD1 binding. Flag-tagged GFI1 forms were 
transiently expressed in Cos7L cells. GFI1 forms were immune purified with anti-
FLAG antibody and coprecipitating, endogenously expressed LSD1 detected in 
immune complexes (IC) by western blot. Equivalent expression and precipitation 









Figure 3.2. SMYD2 mediated methylation at K8 of the SNAG domain contributes 
to repressor function. A. Impact of SMYD2, SETD7 and G9a protein lysine 
methyltransferase expression on transcriptional repression by the WT SNAG 
domain. HEK293 reporter cells were transfected with SNAG-WT:Gal4, SMYD2, 
SETD7 and G9a as indicated. Luciferase assays were performed as described in 
Figure 1B. B. SMYD2 binds the GFI1 SNAG domain. FLAG tagged SMYD2 and 
fusion proteins comprised of SNAG-WT or SNAG-K8L and the Gal4 DNA binding 
domain were expressed in Cos7L cells. FLAG-SMYD2 was immune purified from 
whole cell lysates (WCL) and co-precipitation of the SNAG domain was determined 
by Gal4 immunoblot (WB) of FLAG immune complexes (IC). A dashed vertical line 
indicates a lane that was removed from the film for clarity. C. SMYD2 methylates 
K8 of the SNAG domain. Human recombinant SMYD2 was incubated with WT and 
K8L SNAG domain peptides and [3H]-SAM methyl-donor. Peptide 3H 
incorporation was determined by liquid scintillation. D. SMYD2 augments 
transcriptional repression by the  SNAG domain via K8. SNAG-WT:Gal4 or SNAG-
K8L:Gal4 proteins were expressed independently or in conjunction with SMYD2. 
Luciferase output was measured as previously described. E. Impact of SMYD2 
inhibition on SNAG-mediated transcriptional repression. SNAG-WT:Gal4 
expressing HEK293 reporter cells were treated with SMYD2 inhibitor (LLY-507) as 
shown. Firefly luciferase reporter output was measured and normalized to Renilla 
luciferase control. For luciferase assays, results are expressed as mean +/- SD 








Figure 3.3. K8 methylation favors SNAG—LSD1 binding. A. SNAG domain K8 
methylation strongly favors binding of recombinant, purified human LSD1 (hLSD1). 
Unmethylated (SNAG) or K8 dimethylated (SNAG-K8me2) SNAG peptides 
carrying a biotin moiety were incubated with hLSD1. Biotinylated SNAG peptides 
were purified on streptavidin-conjugated agarose beads. Beads were washed 
extensively in incubation buffer. LSD1 copurifying with SNAG peptides or 
remaining in the supernatant was detected by western blot (WB). B. K8 methylation 
enables SNAG—LSD1 binding from CCRF-CEM extracts. Unmethylated or K8 
dimethylated SNAG domain peptides were incubated with CCRF-CEM extracts as 
noted. Biotinylated peptides were captured on streptavidin-conjugated agarose 
beads, washed and subjected to WB to detect co-purifying, endogenously 








Figure 3.4. K8 is required for LSD1 recruitment and H3K4 demethylation at a GFI1 
target gene. A. LSD1 contributes to SNAG-mediated repression. HEK293 reporter 
cells were transfected with SNAG-WT:Gal4 and LSD1 as indicated. Firefly 
luciferase reporter output was measured, normalized to a Renilla internal control 
and results reported as the mean +/- SD from a representative experiment. B-C. 
Catalytically inactive LSD1 (K661A) (B) and LSD1 inhibition with HCI-2509 (C) 
antagonize SNAG-mediated transcriptional repression. HEK293 reporter cells 
were transfected with SNAG-WT:Gal4 and LSD1 forms or treated with HCI-2509 
as shown. Reporter output was measured as in A. D-F. SNAG-K8L substitution 
impairs LSD1 promoter binding and stabilizes H3K4me2 marks. HEK293 reporter 
cells were transfected with empty vector, SNAG-WT:  and SNAG-K8L:Gal4 as 
indicated. Cells were subjected to crosslinking, harvesting and sonication, then 
chromatin immunoprecipitation (ChIP) was performed using Gal4, LSD1 and 
H3K4me2 antibody coated beads. Quantitative PCR (qPCR) targeting the 
promoter of the integrated reporter (see Figure 1B) was performed using ChIP 
DNA as template. Fold enrichment was determined by the Ct method and 








Figure 3.5. K8 methylation is required for zebrafish primitive erythropoiesis. A. 
Primitive erythropoiesis impaired by gfi1aa depletion is restored by WT GFI1 but 
not by K8L or P2A derivatives. Zebrafish embryos were microinjected at the 1 cell 
stage with a morpholino oligomer blocking gfi1aa pre-mRNA splicing or a content 
matched, scrambled sequence control as indicated (Depletion). Morpholino 
resistant rat Gfi1-WT, Gfi1-P2A or Gfi1-K8L mRNA was coinjected as indicated 
(Rescue). When no depletion or rescue was indicated, mock injections were 
performed as shown. At 48 h postfertilization (hpf) primitive erythropoiesis was 
revealed by o-dianisidine staining. Four representative embryos are shown out of 
more than 60 scored for each experimental condition. Primitive erythropoiesis was 
quantified using a hemoglobinization score from 1 to 4, indicating minimal (1), 
modest (2), moderate (3) and complete (4) hemoglobinization. The percentage of 
embryos with each respective score is reported as a stacked sum graph and 
statistical significance determined using a Wilcoxon-Mann-Whitney test (***, P 
<0.0005). B. Zebrafish LSD1 homolog, kdm1a, depletion impairs zebrafish 
primitive erythropoiesis. Splice blocking kdm1a morpholino and morpholino 
resistant human WT LSD1 mRNA were injected at the 1 cell stage as indicated in 
the table. Primitive erythropoiesis was scored in a blinded fashion at 48hpf on the  








Figure 3.6. GFI1 is required for lymphoid leukemia cell survival. A. CCRF-CEM 
cells are depleted of GFI1. Whole cell lysates were prepared from uninfected 
CCRF-CEM cells or those infected with short hairpin RNA targeting GFI1 (shGfi1) 
or a content-matched scramble control (Control). GFI1 protein expression was 
assessed by western blot with tubulin serving as a protein loading control. B-C. 
GFI1 depletion leads to CCRF-CEM apoptosis and secondary necrosis. CCRF-
CEM cells were transduced with scramble control vector or shGfi1 to deplete GFI1, 
then subjected to flow cytometry analysis. Forward scatter (FSC)/side scatter 
(SSC) identifies discrete cell populations. Gates were established for each 
population and viability assessed by annexin V and propidium iodide (PI) staining. 
Percentages representing viable, early (annexin V+/PI-) and late 
apoptosis/secondary necrosis (annexin V+/PI+) are indicated by quadrant labels 








Figure 3.7. K8 is required for GFI1 progrowth and survival functions in lymphoid 
leukemia cells. A. FLAG-tagged WT, P2A and K8L GFI1 expressing CCRF-CEM 
cell lines were depleted of endogenous GFI1 as indicated. Endogenous GFI1 and 
FLAG-tagged GFI1 expression was assessed by western blot, with tubulin serving 
as a protein loading control. B. K8 methyl defective and LSD1 binding-defective 
GFI1 cell lines have impaired cell growth and viability. Cell viability was determined 
by trypan blue exclusion counting in the indicated cell lines over 7 days following 
shRNA mediated GFI1 depletion. Viable cells per ml over time is reported. C. 
Genes associated with apoptosis regulation are upregulated in CCRF-CEM cell 
lines depleted of endogenous GFI1 and in GFI1 depleted cell lines expressing P2A 
and K8L GFI1 derivatives. Shared upregulated genes (relative to expression in 
naïve CCRF-CEM cells) are clustered in cells depleted of endogenous GFI1 while 
expressing empty vector as well as WT, P2A and K8L GFI1. 82 genes upregulated 
in CCRF-CEM cell lines depleted of endogenous GFI1 while expressing empty 
vector, P2A and K8L but not upregulated in cell lines depleted of endogenous GFI1 
while expressing WT GFI1 were subjected to Gene Ontology (GO) functional term 









Figure 3.8. A working model for GFI1 mediated LSD1/CoREST recruitment and 
transcriptional repression. Presented here is a model for how dual inputs to GFI1 
through concurrent posttranslational modifications (methylation and SUMOylation) 
enable robust transcriptional repression at GFI1 regulated genes. LSD1 and 
CoREST are envisioned to exist in a preformed complex, but their demethylase 
activity would be restricted/limited by a lack of regulatory inputs. The SNAG 
domain has intrinsic affinity for LSD1, which is significantly enhanced by SNAG 
domain methylation on K8 via the action of SMYD2/S-adenosylmethionine (SAM), 
and perhaps altered by other KSKK modifications yet to be explored. Simultaneous 
SUMOylation of GFI1 facilitates an interaction with LSD1/CoREST. LSD1 
demethylase activity on chromatin is activated through an interaction between 
SUMO2/3 assembled on GFI1 and a SUMO interacting motif in CoREST. One 
might see LSD1 binding to GFI1 via the SNAG domain, but without SUMOylation 
and CoREST dependent  stimulation of LSD1 demethylase activity, its impact on 
transcription would be limited.  Likewise, LSD1 could be brought to GFI1 regulated 
genes indirectly through the SUMO—CoREST interaction, but without SNAG 
methylation might be insufficiently stable to have a lasting impact on gene 
expression. This working model will inform our efforts to understand how 
transcriptional control by GFI1 and other SNAG transcription factors is fine tuned 
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GFI1 as a model for studying mechanisms of 
transcriptional repression 
 Growth factor independence 1 (GFI1) is a transcriptional repressor and 
master regulator of normal and malignant hematopoiesis (1). GFI1 is comprised of 
an N-terminal SNAG domain, a C-terminal concatemer of six zinc fingers, and a 
family divergent linker region which separates them (2). GFI1 directly binds 
consensus sequence DNA, utilizing zinc fingers 3, 4, and 5 to do so (3). The SNAG 
domain is the dominant repressive element within GFI1 and individual residues 
within the SNAG domain are required repressor function, while others are 
dispensable (3). 
Based on our work and the work of others, it is reasonable to consider GFI1 
requiring two primary functions for transcriptional repression. First, GFI1 must be 
capable of binding consensus DNA sequences through zinc fingers 3-5. Disruption 
of zinc fingers 3, 4, or 5 abolishes repressor function and mutations within these 
zinc fingers give rise to neutropenia in humans (1, 4). Second, GFI1 must have an 
intact SNAG domain. We provide evidence here that K8 methylation is a critical 
determinant of SNAG domain mediated repression. We and others also 
demonstrate P2 is required for transcriptional repression by GFI1 (3). Additionally, 
we and others find R3, S4, S9, K10, and K11 are largely dispensable for repressor 
function (3). However, a saturating substitution based analysis of residues required 
for SNAG mediated repression has not been performed and other residues within 
the SNAG domain may also contribute to GFI1 repressor function.  
The relatively simple architecture of GFI1 found in the SNAG domain and 
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zinc fingers makes it an ideal transcription factor to study mechanisms of 
transcriptional repression as such a deconstructed system is capable of revealing 
novel insights devoid of other complicating regulatory interactions and inputs. 
Furthermore, only one protein, LSD1, is known to bind the SNAG domain (1). 
Within our already deconstructed system we focused on a four residue KSKK 
motif. Yet, despite focusing on only four amino acids within a 422 amino acid 
protein we found a remarkable degree of regulatory complexity exists within the 
SNAG domain KSKK motif. We suspect this theme will be observed in future 
studies using deconstructed systems. Furthermore, our data provide evidence that 
using deconstructed biochemical systems is a powerful approach for revealing 
deterministic functional relationships. 
Our findings here add to the emerging choreography of posttranslational 
modifications that regulate GFI1 function. In Chapter 2 we describe SUMOylation 
contributes to LSD1/CoREST binding of GFI1. In Chapter 3 we describe how 
methylation also contributes to LSD1 binding to the GFI1 SNAG domain. Taken 
together, these data suggest GFI1 methylation and SUMOylation function as part 
of a series of multiple regulatory inputs that modulate GFI1 function. Within this 
model, we propose SNAG domain methylation and linker region SUMOylation act 
together to facilitate LSD1/CoREST recruitment and enable CoREST dependent 
activation of LSD1 demethylase activity at GFI1 target genes (Figure 3.8). 
Our findings here raise many additional questions regarding the functions 
of GFI1 as well as posttranslational modification of transcription factors generally. 
1) Are methylation events within the SNAG domain KSKK motif combinatorially 
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regulated? And how do methyl mark combinations impact GFI1 function? 2) Is 
there functional cross talk between GFI1 SUMOylation and methylation? And how 
is the deposition of these posttranslational modifications regulated? 3) Are 
methylation events within the GFI1 and p53 KSKK motifs crossregulated? Are 
these methylation events impactful in lymphoid leukemia? 4) What is the functional 
breadth of transcription factor posttranslational modification in the human 
proteome?  
 
Are methylation events within the SNAG domain  
KSKK motif combinatorially regulated? 
Our work here demonstrates SMYD2 mediated methylation at K8 in the 
SNAG domain is a critical determinant of GFI1 mediated transcriptional repression. 
We also find SETD7 methylates K10 of the SNAG domain and G9a methylates 
K11 of the SNAG domain (Figure 4.1). These results indicate the 
methyltransferase activity of SMYD2, SETD7 and G9a is conserved across the 
GFI1 and p53 KSKK motifs. Within p53, KSKK methylation is dynamically 
regulated to alter p53 function and specific methylation events are either 
functionally supportive or antagonistic to one another. It is currently unknown 
whether methylation events are similarly regulated within the SNAG domain to 
modulate GFI1 function.  
Overcoming current in vitro technical limitations. In ascribing 
methyltransferase activities of SMYD2, SETD7 and G9a to the GFI1 SNAG 
domain, we have used a reductionist approach. Our experiments were performed 
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in vitro using the minimum required components for the enzymatic reaction, 
namely, a recombinant enzyme, a peptide substrate and a methyl group donor. 
This reductionist approach is powerful to define sufficiency of an enzyme to 
methylate a substrate, but also may introduce novel activities and false 
positives/negatives. This point is illustrated in our difficulty detecting SMYD2 
mediated K8 methylation by mass spectral approaches, while we readily detect 
K10 and K11L methylation by SETD7 and G9a by mass spec (Figure 4.1). In future 
studies it may be beneficial to use full length proteins as these components are 
more biologically pertinent. Using full length GFI1 may also provide additional 
protein domains and structures not present in the SNAG domain that are required 
for SMYD2 mediated methylation. 
Our in vitro approaches here also use unmethylated SNAG domain 
peptides, an experimental design which presupposes the methyltransferases used 
are capable of acting on peptides devoid of other posttranslational modifications. 
It is reasonable to consider these methyltransferases, and in particular, SMYD2, 
may require posttranslational modification at other SNAG residues for their action. 
Experimentally determining whether SMYD2 and other methyltransferases 
activities are altered by posttranslational modification at other residues remains 
costly and technically difficult. For example, to thoroughly characterize how 
methylation at each of the other KSKK motif lysines impacts SMYD2 activity at K8, 
peptide substrates would need to be synthesized with every possible combination 
of a leucine (or otherwise) substituted residue, as well as un, mono, di, and 
trimethylated lysine states. With five possible states at three residues, 125 (=5^3) 
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unique peptide combinations exist. With current peptide synthesis technologies it 
would be unfeasible and cost prohibitive to synthesize 125 SNAG domain 
peptides. Future peptide synthesis technologies may reduce cost sufficiently to 
warrant such an experimental approach. 
SMYD2, SETD7, and G9a are all available commercially as recombinant 
enzymes. However, as these enzymes are also histone methyltransferases, they 
are typically only validated based on their activity against histone peptide 
substrates. This makes it difficult to differentiate true negatives from false 
negatives when assessing enzyme activities on SNAG peptides. This issue may 
also be a contributing factor to our difficulty detecting SMYD2 mediated 
methylation at K8 by mass spectrometry. 
An alternative approach to screening each methyltransferase’s activity 
against more than 100 unique peptide substrates would be to incubate unmodified 
peptides with combinations of methyltransferases. Only eight possible 
combinations (=2^3) exist when analyzing three methyltransferases (SMYD2, 
SETD7 and G9a), a more technically feasible number of combinations. If SMYD2 
requires distinct methylation states at other lysine residues within the SNAG 
domain for its activity, such an approach would be capable of detecting this activity. 
In the face of complicated methylation patterns, our findings that SETD7 and G9a 
respectively methylate K10 and K11 in an unmodified peptide would allow us to 
differentiate each enzyme’s function. If other confounding additional methylation 
events were observed in this approach, individual activities could be ascribed 
based on each enzymes activity on an unmodified peptide or peptides with specific 
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modifications. Using a limited number of modified synthesized peptides in these 
reactions could help clarify confounding activities as well as directly validate each 
enzymes activity in the presence of a specific modification. This unbiased 
approach allows for all possible combinations of methylation events and is likely a 
more technically feasible starting point for thoroughly characterizing each 
methyltransferase’s activity in the SNAG domain. 
Similar technical challenges exist for thoroughly defining the demethylase 
activity of LSD1 within the SNAG domain. Unlike LSD1 demethylase activity at 
K370 in p53, we fail to detect LSD1 demethylase activity against a K8 dimethylated 
SNAG domain peptide in vitro, relative to an H3K4 dimethylated peptide (Figure 
4.2). This lack of activity may be due to a number of issues. We have yet to test 
whether LSD1 is capable of demethylating K8 monomethylated SNAG domain. 
Also, using SNAG domain peptide substrates abolishes the potential contribution 
of other portions of GFI1 to LSD1 demethylase activity. We find substitution at the 
K239 SUMO acceptor residue impairs LSD1 binding to GFI1, suggesting additional 
elements outside the SNAG domain may regulate LSD1 binding and demethylase 
activity (Figure 2.8). Using full length GFI1 protein substrates may also reveal 
activities of LSD1 in the SNAG domain masked by our current approaches. 
Characterizing GFI1 methylation status in vivo.  It will also be informative to 
define GFI1 methylation status in vivo. SMYD2, SETD7, G9a and LSD1 are 
expressed in the majority of normal human tissues and are often misexpressed in 
cancer, suggesting complex GFI1 methylation statuses may exist in vivo  (5). We 
have begun to characterize GFI1 methylation status in lymphoid leukemia, using 
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the T-lymphoblast cell line CCRF-CEM. Within GFI1 immunepurified material, we 
have detected GFI1 peptide fragments by mass spectrometry. We continue to 
optimize this method, including using an enzyme that will cut appropriately to allow 
detection of SNAG domain lysine methylation. In silico predictions suggest 
chymotrypsin digestion would appropriately produce a peptide fragment 
(6LVKSKKAHSY15) spanning the KSKK motif. We are currently proceeding with 
these technical considerations. 
Developing antibody reagents capable of recognizing specific methylated 
forms of GFI1 will also be powerful to define GFI1 methylation status in vivo. 
Determining pertinent methylation states in vitro may also minimize the number of 
antibodies needed to be produced, minimizing the associated costs. Antibody 
reagents would allow for functional characterization of methylated GFI1 forms. 
Methyl specific antibodies could be applied in coimmunoprecipitation and ChIP-
seq experiments to define methylation dependent GFI1 interactions as well as 
methylation dependent DNA binding in the genome.  
 
Is there functional cross talk between GFI1 SUMOylation  
and methylation? 
 Our findings that both SUMOylation and methylation contribute to GFI1 
function through augmenting LSD1/CoREST binding raises the question of 
whether these modifications are coordinately regulated. We show here that 
SUMOylation machinery component PIAS3 and the methyltransferase SMYD2 
both physically interact with GFI1 (Figure 2.1 and Figure 3.2). However, a direct 
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interaction between SMYD2 and PIAS3 has not been described, suggesting 
methylation and SUMOylation inputs on GFI1 may be independent of one another 
(6). SUMOylation/ubiquitination as well as methylation/acetylation crosstalk is 
prevalent in cells (7, 8). However, evidence suggesting SUMOylation/methylation 
crosstalk is currently limited (7, 8). Developing SUMO and methyl specific GFI1 
antibodies will be useful for determining if and how these posttranslational 
modifications are regulated on GFI1, including the order of their addition and if the 
presence of one modification promotes or deters addition of the other. 
 
Are methylation events within the GFI1 and p53 KSKK  
motifs cross regulated?  
 We find the methyltransferases SMYD2, SETD7 and G9a have conserved 
activities for lysines within the GFI1 and p53 KSKK motifs. However, it remains 
unknown whether GFI1 and p53 methylation status affect one another, or whether 
there are functional consequences of such regulation.  
 Gfi1 antagonizes p53 apoptosis functions in multiple lymphoid leukemia 
mouse models (9). In leukemia cells, Gfi1 directly binds p53 and prevents 
expression of p53 responsive genes such as BAX (9). Gfi1 ablation also sensitizes 
mouse thymocytes to apoptosis following γ-irradiation (9). Furthermore, biallelic 
deletion of Gfi1 confers 100% survival in mice with Notch1 driven T-cell leukemia 
(9). These results implicate a direct functional relationship between GFI1 and p53 
and GFI1 inhibition may represent a therapeutic opportunity in lymphoid leukemia.  
 In addition to survival benefits, biallelic Gfi1 deletion also increases K372 
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methylation on p53, a mark associated with p53 activation (9). These results 
suggest GFI1 may directly or indirectly influence p53 methylation status. However, 
the methylation status of GFI1 in lymphoid leukemia is currently unknown. It is also 
not known whether simply the presence of GFI1 dictates p53 methylation status or 
whether GFI1 methylation specifically augments p53 methylation.  
 GFI1 and p53 methyl specific antibodies would allow for characterization of 
GFI1/p53 methylation status cross talk, as well as the functional impact of this 
cross talk. These reagents would allow for determining the methylation status of 
GFI1 and p53 when they are physically associated. Antibody reagents would also 
be capable of determining the methylation status of each protein when it is bound 
at mutually exclusive and/or shared target genes. Correlating occupancy of methyl 
specific GFI1 and p53 forms with proximal histone marks and transcriptional status 
would also provide powerful insights into GFI1/p53 methylation dynamics and their 
methylation dependent functions in the genome. 
 Genome editing CRISPR-Cas9 technology will also be a powerful technique 
for characterizing GFI1 and p53 methylation crosstalk. CRISPR-Cas9 mediated 
substitution at methyl acceptor lysine residues would reveal how loss of 
methylation at one lysine affects methylation status at other lysines, both within the 
same protein or within the other respective protein.  
 Notch is a potent driver of T-cell leukemia and Gfi1 ablation is protective 
against Notch1 driven leukemias, likely through derepression of p53 function (9, 
10). We have also demonstrated the Notch1-intracellular domain (N1-ICD) 
interacts directly with GFI1 (Figure 4.3) (11). Furthermore, N1ICD stabilizes LSD1 
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interaction with GFI1 (Figure 4.3).  Future experiments will be needed to determine 
how Notch impacts GFI1 and p53 methylation statuses.  
  
What is the functional breadth of transcription factor  
posttranslational modification in the  
human proteome?  
 Our findings here add GFI1 to a growing list of transcription factors and 
other nonhistone proteins regulated by lysine methylation. Transcription factors 
regulated by lysine methylation are predominantly factors with functions in cell fate, 
differentiation, and survival, many of which are disregulated in cancer. These 
master regulators include: p53, RB, E2F1, STAT3, MYOD, RELA/p65, AR, ERα, 
and CEBPβ (12, 13). The functional impact for many of these methylation events 
remains unclear.   
 Complete characterization of posttranslational modifications within the 
human transcription factor proteome remains a technically challenging effort. 
However, recent efforts have successfully profiled the monomethylation proteome 
in four cancer cell lines and a human liver cancer sample (14). This report indicates 
methylation events are highly context and cell type specific, with only 27 conserved 
methylation events observed across cell lines and primary tumor (14).  
 These methods are promising for discovering novel methylation events but 
are incapable of identifying methyltransferases and demethylases responsible for 
these events and are also unable to identify the functional consequences of these 
methylation events. Array peptide screening methods are promising for identifying 
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how specific posttranslational modifications alter function through augmenting 
protein/protein interactions. These methods use an array format to subject 
peptides with specific posttranslational modifications to protein bacterial 
expression libraries (15).  
Array peptide screening methods could prove powerful for assessing the 
functional impact of specific posttranslational modifications, however; hypothesis 
driven investigation may be equally if not more productive. Hypothesis driven 
investigation enabled us to identify a shared KSKK motif between GFI1 and p53. 
We were subsequently able to demonstrate lysine methylation within this motif is 
conserved across both proteins. Furthermore, these hypothesis driven insights 
provided compelling questions for future study, more so than descriptive proteomic 
screening approaches. 
 Many sites of methylation in transcription factors and other nonhistone 
proteins reside within a loosely conserved KSKK motif (Table 1.1). As mentioned 
previously, GFI1 and p53 share a completely conserved KSKK motif. However, 
E2F1 is methylated within a KKSK motif. RELA/p65 is methylated within KSIMKK 
motif. RB is methylated within a KPLKK motif. TAF7 and TAF10 are both 
methylated within a KSKD motif. ERα is methylated within a KRSKK motif. IRF1 is 
methylated within a KSKS motif. NR1H4 is methylated within a KSKR motif (13). 
A Basic Local Alignment Search Tool (BLAST) search estimates roughly 330 
genes encode a KSKK motif, 266 genes encode a KSKS motif, 195 genes encode 
a KSKR motif, 170 genes encode a KSKD motif, 20 genes encode a KRSKK motif, 
17 genes encode a KPLKK, motif and 5 genes encode a KSIMKK motif (16). This  
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impressive number of proteins suggests many lysine methylation events within 
loosely conserved KSKK motifs remain to be identified as well as functionally 
characterized.  
 
Conclusions: GFI1 is a model transcription factor for 
studying mechanisms of transcriptional regulation 
 Transcription factors are master regulators of cell fate, function, and 
survival. As such, understanding how transcription factors exert their 
transcriptional regulatory functions is critical for understanding their contribution to 
normal and disease states. During my thesis work, I studied how the transcription 
factor GFI1 carries out transcriptional repression through the action of its coeffector 
LSD1. My thesis work describes novel mechanisms of transcriptional repression 
by GFI1, and provides a rare mechanistic understanding for how posttranslational 
modifications modulate transcription factor functions. From the data generated 
during my thesis work, we propose GFI1 is subject to dual regulatory inputs where 
linker region SUMOylation and SNAG domain methylation serve to stabilize and 
activate LSD1/CoREST for H3K4 demethylation and repression of GFI1 target 
genes. We also speculate towards cross talk between GFI1 SNAG domain and 
p53 methylation status, given a shared set of methylation regulatory enzymes. 
Similar approaches to what we have taken here will allow future work to further 
define the functional breadth of transcription factor posttranslational modifications 
in normal and disease states.
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Figure 4.1. SETD7 methylates K10 of the SNAG domain and G9a methylates 
K11 of the SNAG domain. Y and B ion fragmentation schematic is shown on top 
with each cleavage and resulting peptide indicated as staggered lines. Atomic 
mass units (AMU) of each y and b ion fragmentation species is shown in the 
table. A gain of 14.02 AMU, consistent with the addition of a single methyl group, 
at position 10 is observed in the presence of SETD7. Likewise, a 14.02 AMU 






Figure 4.2. LSD1 does not demethylate K8 dimethylated SNAG domain peptide 
in vitro. Recombinant human LSD1 was incubated with either K8 dimethylated 
SNAG domain peptide or K4 dimethylated histone H3 peptide as indicated. LSD1 
activity was assessed using the LSD1 Inhibitor Screening Assay Kit from 
Cayman Chemical according to manufacturer protocols. Enzyme activity was 






Figure 4.3. Notch1 intracellular domain (N1ICD) stabilizes LSD1 interaction with 
GFI1. FLAG-tagged GFI1 forms were transiently expressed in Cos7L cells. GFI1 
forms were immune purified with anti-FLAG antibody and coprecipitating 
endogenously expressed LSD1 was detected in immune complexes (IC) by 
western blot (WB). 
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